##  [# ETF Explainer: ARKK](/sections/etf-report-departments/etf-explainer-arkk) 

 

# ETF Explainer: ARKK

 

 

ARK’s actively managed fund broadly focused on disruptive innovation has exceled lately.



 

 

 

 

 [![HeatherBell_green_bg](/sites/default/files/styles/author_image_icon/public/2023-03/heather2.png?itok=5J9vBlda)](/contributors/heather-bell) 

[By Heather Bell](/contributors/heather-bell)

 Jul 31, 2020

 Edited by: Heather Bell

 

 

     Share  <a class="a2a a2a_button_email"> Email </a><a class="a2a a2a_button_linkedin"> LinkedIn </a><a class="a2a a2a_button_facebook"> Facebook </a><a class="a2a a2a_button_x"> X (Twitter) </a> 

 

 

 

 

 

 

 

 

  
            googletag.cmd.push(function() {
                googletag.display('js-dfp-tag-article_page_302x26');
            });
    
    

 

 

  

 



 

 

  Loading 

 

 



 

 

**ARK Innovation ETF**Each month, we look at an ETF selected by ETF.com based on its performance and importance to investors. This month, we consider the performance of the $5 billion [ARK Innovation ETF (ARKK)](/ARKK), which has been one of the best-performing ETFs of 2020. All the companies mentioned below are holdings in ARKK, unless otherwise noted (\*).

[![ETFExplainerVTV](/sites/default/files/images/Magazines/ETF%20Report/2020/07/ETFExplainerARKK_fig1.jpg)](/sites/default/files/images/Magazines/ETF%20Report/2020/07/ETFExplainerARKK_fig1b.jpg)

*For a larger view, please click on the image above.*



**AUG 5** Digital payments company Square falls sharply over the course of two trading days after a disappointing second-quarter earnings report and lowered guidance for the third quarter.

**SEP 11** Genome sequencing firm Illumina sees its share price boosted after the U.K. announces a $250 million genome research project that will rely on Illumina’s technology.

**NOV 7** Roku reports its third-quarter results. Although it exceeded revenue expectations, the company’s loss for the quarter drove its share price down by nearly 15% in after-hours trading.

**FEB 4** Tesla sees its stock price increase 36% to reach a new high as the head of Baron Capital\* suggests the carmaker could see $1 trillion in revenue in 10 years.

**MAY 11** CRISPR Therapeutics’ stock price jumps 15% in two days after the FDA awards the company’s blood disease treatment CTX001 the designation “regenerative medicine advanced therapy.”

**JUN 22** Medical genetic testing company Invitae announces it will acquire another genetic testing company, ArcherDX,\* in a $1.4 billion deal, boosting the former’s share price significantly.

*Source: Bloomberg; data for 6/30/2019-6/30/2020*





 

 

 [ Heather Bell ](/contributors/heather-bell) 

 

 

  Heather Bell is a former managing editor of etf.com. She has also held editorial positions at Dow Jones Indexes and Lehman Brothers. Bell is a…   [View Bio](/contributors/heather-bell)

 



 

 


 Related Topics  [Active Management](http://www.etf.com/topics/active-management) 

 [Alpha-Seeking](http://www.etf.com/topics/alpha-seeking) 

 [ARK](http://www.etf.com/topics/ark) 

 [Broad-based](http://www.etf.com/topics/broad-based) 

 [Equity](http://www.etf.com/topics/equity)